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Polyarteritis nodosa (PAN) is a systemic
autoimmune vasculitis characterized by
necrotizing inflammatory lesions of the
medium-sized and small muscular arter-
ies, preferentially at vessel bifurcations,
resulting in microaneurysms formation,
aneurysmal ruptures with hemorrhage,
thrombosis and consequently, organs
ischemia or infarction. It usually appears
in middle and older age, without gender
predilection (Jennette et al., 1994).
PAN shows a wide variety of symptoms,
including general symptoms, neurological,
skin, renal, and gastrointestinal involve-
ment. In particular, skin lesions, charac-
terized by multiple firm waxy papules,
subcutaneous nodules, livedo reticularis,
ulcers and gangrene, are observed in
25–60% of patients with PAN (Cohen
et al., 1980). In most of the cases,
the disease is treated with glucocorti-
coids and cyclosphosphamide (conven-
tional treatment). However, rituximab is
the first FDA-approved drug (on April
19, 2011) for any form of vasculitis.
There is no known cause or cure for
vasculitis. Rituximab works by affecting
the action of and eliminating B cells,
which are cells of the immune system
that have a number of actions. It was
initially developed for treatment of a
type of lymphoma, and since has been
found to be effective for autoimmune dis-
eases, including rheumatoid arthritis and
now ANCA-associated vasculitis (Cohen
Tervaert, 2011).
Refractory patients are exposed to
many complications, notably accelerated
atherosclerosis. The etiologies of systemic
vasculitis are yet unknown. However,
dysregulation and/or enhanced expression
of pro-inflammatory substances may be
involved in the pathogenesis of these dis-
eases. Tumor necrosis factor (TNF)-alpha
is a pro-inflammatory cytokine produced
primarily by cells of the macrophage-
monocyte lineage. The biologic effects
of TNF-alpha include adhesion molecule
expression, synthesis of proinflammatory
cytokines and chemokines, activation of
immune system cells (T-cells, B-cells, and
macrophages), and inhibition of regula-
tory T-cells; thus, it may directly par-
ticipate in vascular inflammation as well
as in endothelial cell death via apopto-
sis (Bansal and Houghton, 2010; Jarrot
and Kaplanski, 2014). In addition, TNF-
alpha may play a role in neutrophil
“priming” inducing membrane expres-
sion of proteinase-3 or myeloperoxi-
dase, which are subsequently recognized
by ANCA (anti-neutrophil cytoplasmic
antibodies) in ANCA-associated vasculitis
(AAV) (Radford et al., 1999). Also, ele-
vated levels of plasma TNF-alpha have
been shown to correlate with active
glomerulonephritis (a variant of vasculi-
tis) and elevated in vitro TNF stimulated
peripheral blood mononuclear cells and
CD4+ T cells (Lúdvíksson et al., 1998).
Etanercept is a fusion protein com-
posed of 2 extracellular p75 TNF recep-
tor domains linked by the Fc portion of
human IgG1. It binds to and neutralizes
biologically active TNF-alpha. It has been
approved by the FDA for the treatment
of rheumatoid arthritis, polyarticular juve-
nile idiopathic arthritis in patients aged
2 years or older, psoriatic arthritis, anky-
losing spondylitis and plaque psoriasis
according to the results of randomized
phase III studies. The most common side-
effects of etanercept are reactions at the
injection site (usually redness and some-
times itching), a blocked or runny nose,
nausea, mild fever, headaches, dizziness,
a rash, and stomach symptoms. More
serious and infrequent adverse events are
heart failure, infections and skin cancers.
In this report we show a case of suc-
cessful treatment of refractory PAN with
etanercept. A 10-year-old patient, with
no remarkable medical history, affected
by systemic vasculitis was treated with
first-line glucocorticoids for 2 years. At
relapse, he was treated with intravenous
cyclophosphamide (IVCY). After three
IVCY pulses, the patient’s condition dete-
riorated with subacute polyarthritis, myal-
gias and livedo. Furthermore, multiple
malacic lesions were observed at brain
MRI (Magnetic Resonance Imaging) and
signs of sensory-motor polyneuropathy
were documented on electromyograms of
the legs.
Histological examination of neuromus-
cular biopsy found a vasculitis with fibri-
noid necrosis confirming the diagnosis of
PAN. Thus, he was initially treated with
60mg/day of prednisolone, followed by
1000mg/day of IVCY therapy according to
the European League Against Rheumatism
(EULAR) recommendations for the man-
agement of small and medium vessel vas-
culitis (European Vasculitis Study Group,
2009). However, he presented resistance to
high dose corticosteroid and IVCY ther-
apy, thus he was treated with high dose
intravenous immunoglobulin (IVIg) ther-
apy that, according to the literature, can
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show efficacy in such cases with a good
safety profile (Sroa et al., 2010).
After 2 months of IVIg treatment
(0.4 g/kg body weight/day for 5 con-
secutive days every month), a partial
regression of the disease was achieved.
Clinical progression was observed after 6
months. Thereafter, the patient was treated
with oral thalidomide (initial dosage
100mg/day) obtaining a rapid control of
signs and symptoms. The treatment was
continued for 6 months with a lower daily
dose (50mg/day) until the occurrence of a
severe peripheral neuropathy.
Considering (i) patient age, (ii) clin-
ical conditions, (iii) disease progression,
(iv) previous treatments, and (v) scientific
literature reporting involvement of TNF
pathway and response to anti-TNF agents
in systemic vasculitis, off-label use of etan-
ercept (Bartolucci et al., 2002; Sonomoto
et al., 2008) was proposed (25mg subcuta-
neously twice a week).
Interestingly, after starting the treat-
ment, symptoms and lesions improved
without adverse effects. A clinical response
was registered after 2months, withmarked
improvement in arthralgia, resolution of
ulcerations and erythema nodosum and
reduction of fatigue. He shows persis-
tent clinical remission after 2 years of
treatment. At present, the dosage has
been adjusted according to age and
weight and he is on treatment with
etanercept 50mg subcutaneously once
a week.
Our report, as few cases in litera-
ture (Feinstein and Arroyo, 2005; Brik
et al., 2007; Guillevin and Pagnoux, 2007;
Braun-Moscovici et al., 2008; Eleftheriou
et al., 2009; Valor et al., 2013; Zoshima
et al., 2013), supports a role of anti-TNF
therapy in rare systemic vasculitis and,
indirectly, it gives evidence that increased
levels of TNF-alpha may play a critical role
in the inflammatory process associated
with PAN. Preliminary data suggest that
other several forms of vasculitis appear
responsive to TNF antagonists (Behçet’s
disease, Churg-Strauss vasculitis and giant
cell arteritis).
Despite aggressive medical manage-
ment, 22.4% of patients affected by
PAN die within 5 years, and of the
survivors, medication-induced morbidity
is frequent. Thus, there is great need
of basic studies on the pathogenic
mechanisms underlying these disor-
ders as well as of treatments with high
safety and efficacy. Treatment with
etanercept could be considered when
standard therapies are unsuccessful or
contra-indicated.
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